JURNAL

ACUTE PANCREATITIS IN PATIENTS WITH

TYPE 2 DIABETES
MELLITUS TREATED WITH DIPEPTIDYL
PEPTIDASE-4 INHIBITORS
N

A
M
A
: S I T T I A U L I A H I D AYAT
N
I
M
: 10542 0329 11
PEMBIMBING
: D R . J I M M Y G U N A R D I TA N Z I L ,
SPPD

ABSTRACT
DPP IV Inhibitors are approved for use in
monotherapy or in combination therapy for
patients with T2DM.
Numerous report of DPP IV Inhibitors induced
Acute Pancreatitis especially from U.S Food and
Drug Administration Adverse Event Reporting
System.

 This study is designed to evaluate DPP IV

Inhibitors induced Acute Pancreatitis via the
spontaneous Adverse Drug Reactions (ADR).

T2DM
Is a chronic, progressive illness that requires
continuing medical care to prevent acute
complications and to reduce the risk off long term
complications.
According to the recommendation of ADA, the
main therapeutic goal is the achievement and
maintenance of glycemic levels as close to the
non diabetic range as possible (HbA1C < 7%)

ACUTE PANCREATITIS
Is an inflammatory condition of pancreas which
characterized clinically by abdominal pain and
the elevated levels of pancreatic enzymes such
as amylase and lypase in the blood.
A.P. Due to medications is rare (0.3-1.4%). The
pathological way was not fully understood, these
mechanism includes immunology reactions, direct
toxic effect, accumulation of a metabolyte.

 Approximately the length of hospitalization for

A.P. is 5 to 6 days. One case was defined as
serious Adverse Drug Reactions (ADR) because
the hospitaliation lasted more than 7 days, while
the other just 2-5 days.

 In 4 of 2305 cases, it is suspected that DPP IV

inhibitors induced moderated to serious Acute
Pancreatitis.

CONCLUSION
The incidence of DPP IV inhibitors induced Acute
Pancreatitis in patients T2DM is rare.
There are insufficient data to determine if there is
a causal relationship at present. Others factors
may also include the etiology of Acute
Pancreatitis beyond drugs.

 DPP IV are still reasonable options for T2DM.